As between the sponsoring organisations, the results of the study will be the sole and exclusive property of Oxford University. Oxford will initiate and control the filing of any patent applications. Oxford has granted NFCR an exclusive first option to negotiate in good faith a royalty-bearing licence over the results for further drug development. Any royalties NFCR receives from any licensing will be granted back to Oxford University as research funding. Oxford reserves a royalty-free, non-exclusive licence to use the intellectual property internally, in connection with Oxford’s teaching, research and public service mission.